- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01536106
Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients. (AMIRST)
Intracoronary Infusion of Concentrated Autologous Bone Marrow Mononuclear Cells in Acute Myocardial Infarction Patients Utilizing a Novel Point-of-Care Device for Rapid-Delivery of Stem Cells (AMIRST)
The primary objective of the study is to determine the feasibility and safety of intracoronary administration of autologous bone marrow derived mononuclear cell product in patients at risk for clinically significant cardiac dysfunction following AMI.
The secondary objective of the study is to assess the effect on cardiac function and infarct region perfusion. A concurrent placebo control patient group meeting eligibility but not receiving autologous bone marrow derived stem cells will be evaluated similar to the treated group to assess the rate of significant spontaneous improvement in cardiac function.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Emerging evidence indicate that progenitor stem cells derived from bone marrow can be used to improve cardiac function in acute myocardial infarction patients. There is a great potential for stem cell therapy, using a variety of cell precursors to contribute to new blood vessel formation and muscle preservation in the myocardial infarct zone. The administration of cells via an infusion through the infarct related artery appears to be feasible and result in a clinical effect in some studies. Across the globe AMI is the leading cause of morbidity and mortality. This cannot be prevented by optimal standard therapies i.e. balloon or stent dilation of the infarct vessels.
The study is a double blind, placebo controlled, randomized, multicenter trial. Male or female patients between 18-75 years with first incidence of Acute Myocardial Infarction(AMI) and LVEF less than or equal to 40% are included in the study. Patients who have undergone successful percutaneous intervention (PCI) within ≤ 24 hours after onset of symptoms (PTCA/stent) or / and Thrombolysed patients having TIMI-3 flow are eligible to take part in the study.
A total of 30 subjects will be recruited and randomly assigned to receive concentrated BMMNC or placebo. All patients will undergo bone marrow aspiration within 3-10 days from the index event(infarction). Bone Marrow(BM) will be processed utilizing point of care technology. Following cell processing, the concentrated BMMNC or placebo control is infused directly into the infarct related artery using the stop flow method. Clinical follow up for all the subjects at 1,30, 60, 90, 180 and 360 days will be performed from the day of the procedure, with primary and secondary end points evaluated for both study arms.
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Kenneth Harris, MS
- Telefonnummer: 13234207766
- E-post: ken.harris@totipotentrx.com
Studer Kontakt Backup
- Navn: Venkatesh Ponemone, PhD
- Telefonnummer: 911244976860
- E-post: ponemone@totipotentrx.com
Studiesteder
-
-
-
Hyderabad, India, 500034
- CARE Hospitals, Banjara Hills
-
Ta kontakt med:
- Sreenivas A Kumar
- Telefonnummer: 040-30418126
- E-post: arramraj@yahoo.com
-
Hovedetterforsker:
- Sreenivas A Kumar, MD, DM, FACC
-
Underetterforsker:
- Venkatesh Ponemone, PhD
-
New Delhi, India, 110025
- Fortis Escorts Heart Institute and Research Centre
-
Underetterforsker:
- Venkatesh Ponemone, PhD
-
Ta kontakt med:
- Ashok Seth, FRCS, FSCAI
- Telefonnummer: 911147134232
- E-post: ashok.seth@fortishealthcare.com
-
Ta kontakt med:
- Vinay Sanghi, MD
- Telefonnummer: 911147135000
- E-post: vinay.sanghi@fortishealthcare.com
-
Hovedetterforsker:
- Ashok Seth, FRCS, FSCAI
-
Underetterforsker:
- Upendra Kaul, MD, DM, FACC
-
Underetterforsker:
- Vishal Rastogi, MD, DM
-
Underetterforsker:
- Vinay Sanghi, FACP,FACC
-
Underetterforsker:
- Mona Bhatia, MD
-
New Delhi, India, 110070
- Fortis Flt. Lt. Rajan Dhall Hospital
-
Underetterforsker:
- Venkatesh Ponemone, PhD
-
Underetterforsker:
- Mona Bhatia, MD
-
Ta kontakt med:
- Upendra Kaul, MD
- Telefonnummer: 911147135000
- E-post: upendra.kaul@fortishealthcare.com
-
Ta kontakt med:
- Tapan Ghose, MD
- Telefonnummer: 911147134232
- E-post: tapan.ghose@fortishealthcare.com
-
Hovedetterforsker:
- Upendra Kaul, MD, DM, FACC
-
Underetterforsker:
- Tapan Ghose, MD
-
Underetterforsker:
- Ripen Gupta, MD
-
Underetterforsker:
- Ranjan Kachru, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or Female of age 18 - 75 years
- Incidence of first myocardial infarction
- Acute STEMI with LV hypokinesia involving anteroseptal, lateral or inferior walls
- LVEF < 40% pre-intervention
- Successful percutaneous intervention (PCI) within ≤ 24 hours after onset of symptoms (PTCA/stent) or / and Thrombolysed patients having TIMI-3 flow.
- Written informed consent
Exclusion Criteria:
- Multi-vessel coronary disease requiring surgical intervention (CABG) or left main coronary artery disease > 50% blockage
- Previous history of CABG
- Pulmonary edema
- Cardiogenic shock
- Myocarditis
- Renal or hepatic dysfunction
- Hematologic disease
General Exclusion Criteria:
- Alcohol or drug dependency, active or uncontrolled acute myocarditis
- HIV, HBV, or HCV infections
- Evidence of malignant or hematological diseases
- Metal implants of any kind
- Claustrophobia
- Renal insufficiency
- History of bleeding disorder
- Anemia (haemoglobin <8.5mg/dl)
- Platelet count <100,000/ml
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Treatment
Implantation of bone marrow derived mononuclear cells
|
Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
Andre navn:
|
Placebo komparator: Placebo Control
Infusion of autologous peripheral blood
|
Intracoronary infusion of autologous peripheral blood.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of adverse events as a measure of safety
Tidsramme: 12 Months
|
Feasibility and safety of Intracoronary infusion of autologous BMMNCs processed through intraoperative point of care technology, freedom from arrhythmia's.
|
12 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Changes in the global Left Ventricular Ejection Fraction(LVEF), LV volumes-End Systolic Volume (ESV) and End Diastolic Volume (EDV), infarct size, myocardial mass, myocardial viability and regional wall motion abnormalities.
Tidsramme: 12 Months
|
Changes in the global Left Ventricular Ejection Fraction(LVEF), LV volumes-End Systolic Volume (ESV) and End Diastolic Volume (EDV), infarct size, myocardial mass, myocardial viability and regional wall motion abnormalities measured by Cardiac MRI and assessed by central Core lab.
|
12 Months
|
Major adverse cardiac events (MACE)
Tidsramme: 12 Months
|
MACE was defined as the composites of any cause of death, myocardial infarction, revascularization of the target vessel, re-hospitalization for heart failure, and life-threatening arrhythmia.
|
12 Months
|
Quality of life
Tidsramme: 12 Months
|
Quality of life assessment is done using short-form 36, Minnesota living with heart failure questionnaire and Seattle Angina Questionnaire
|
12 Months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studieleder: Venkatesh Ponemone, PhD, TotipotentRX Cell Therapy Pvt. Ltd.
- Studiestol: Kenneth Harris, MS, TotipotentRX Cell Therapy Pvt. Ltd.
- Hovedetterforsker: Ashok Seth, FRCP, FACC, Fortis Escorts Heart Institute and Research Centre
- Hovedetterforsker: Upendra Kaul, MD,DM, FACC, Fortis Flt. Lt. Rajan Dhall Hospital
- Hovedetterforsker: Sreenivas A Kumar, MD, DM, FACC, CARE Hospitals, Hyderabad, India
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J. 2011 Jul;32(14):1748-57. doi: 10.1093/eurheartj/ehq455. Epub 2010 Dec 2.
- Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010 Jul;12(7):721-9. doi: 10.1093/eurjhf/hfq095. Erratum In: Eur J Heart Fail. 2013 Mar;15(3):360.
- Dohmann HF, Silva SA, Sousa AL, Braga AM, Branco RV, Haddad AF, Oliveira MA, Moreira RC, Tuche FA, Peixoto CM, Tura BR, Borojevic R, Ribeiro JP, Nicolau JC, Nobrega AC, Carvalho AC. Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. Trials. 2008 Jul 3;9:41. doi: 10.1186/1745-6215-9-41.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- TPRX/POC/BMSC/AMIRST/1.0
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Akutt hjerteinfarkt
-
Kitasato UniversityRekrutteringAterosklerose | Akutt koronarsyndrom | Stabil angina | Koronar; Iskemisk | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
University Hospital, Strasbourg, FranceAvsluttetST Elevatation Myocardial Infarction (STEMI)Frankrike
-
VesalioRekrutteringSegment Elevation Myocardial Infarction (STEMI)Sveits
-
AstraZenecaFullførtHjerteinfarkt | Segment Elevation Myocardial Infarction (STEMI)Australia, Frankrike, Italia, Spania, Storbritannia, Sverige, Tyskland, Ungarn, Danmark, Østerrike, Canada, Nederland, Algerie
-
Capital Medical UniversityFullførtTransradial Approach, Primær PCI, ST-segment Elevation Myocardial InfarctionKina
-
University of Southern CaliforniaAktiv, ikke rekrutterendeNSTEMI - Ikke-ST Segment Elevation MI | Akutt koronarsyndrom (ACS) | STEMI - ST Elevation Myocardial Infarction (MI) | Ustabil angina (UA)Forente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
-
Sichuan Provincial People's HospitalPåmelding etter invitasjonRest Gated Myocardial Perfusion Imaging ved hjertesviktKina
-
Azienda Ospedaliero Universitaria Maggiore della...Università degli Studi del Piemonte Orientale "Amedeo Avogadro"Rekruttering
Kliniske studier på Autologous Bone marrow mononuclear cells
-
Michael SekelaFullførtKronisk iskemisk hjertesykdomForente stater
-
CliPS Co., LtdFullførtLimbus Corneae insuffisienssyndrom | Limbus CorneaeKorea, Republikken
-
Avita MedicalBiomedical Advanced Research and Development AuthorityAvsluttet
-
Gradalis, Inc.Roche-GenentechFullførtLivmorhalskreft | Eggstokkreft | Livmorkreft | Avansert gynekologisk kreftForente stater
-
Gradalis, Inc.Fullført
-
Gradalis, Inc.FullførtStadium IV Eggstokkreft | Stadium III EggstokkreftForente stater
-
Gradalis, Inc.FullførtStadium IV Eggstokkreft | Stadium III EggstokkreftForente stater
-
Gradalis, Inc.AvsluttetSarkom | Neoplasmer | Neoplasmer, bindevev og mykt vev | Neoplasmer etter histologisk type | Sarkom, Ewing | Neoplasmer, beinvev | Neoplasmer, bindevev | Ewing Sarkom | Sjeldne sykdommer | Ewings svulst metastatisk | Ewing familie av svulster | Ewings sarkom metastatisk | Ewings svulst tilbakevendendeForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtAkutt myeloid leukemi som oppstår fra tidligere myelodysplastisk syndrom | Myelodysplastisk syndrom | Tilbakevendende akutt myeloid leukemi | Blastfase kronisk myelogen leukemi, BCR-ABL1 positiv | Tilbakevendende kronisk myelogen leukemi, BCR-ABL1 positiv | Terapierelatert akutt myeloid leukemi | de... og andre forholdForente stater